|Bid||34.48 x 2200|
|Ask||34.49 x 1000|
|Day's Range||34.79 - 37.08|
|52 Week Range||34.79 - 80.75|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 10, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||65.19|
(Bloomberg) -- Nobel laureate economist Joseph Stiglitz is facing a wave of criticism from peers after he claimed crisis-prone Argentina is witnessing “an economic miracle.”Most Read from BloombergCrypto Crash Erases More Than $1 Trillion in Market Value‘Lethal’ U.S. Military Aid Begins Arriving in UkraineBitcoin Has Lost Half Its Value Since Hitting Record HighBitcoin Chart Hints at Possible Floor for SlideNasdaq 100’s Unrelenting Declines Ring a Dot-Com Bust Alarm BellStiglitz penned a Project
The shakeup comes after Twitter co-founder Jack Dorsey stepped down as chief executive in November, handing the reins to top deputy Parag Agrawal, who has since reorganized the leadership structure of the social media company. Twitter did not specify whether the departures were voluntary. Peiter Zatko, a famed hacker more widely known as "Mudge," was appointed head of security in 2020 after Twitter suffered a security breach that allowed hackers to tweet from verified accounts for public figures including billionaire Bill Gates and Tesla CEO Elon Musk.
Novavax has been both a promising and frustrating stock to own recently. It's promising in the sense that its COVID-19 vaccine candidate could give the company a slice of what's proving to be a very large pie. The frustrating part about Novavax is that it has continually pushed back its schedule for applying to the U.S. Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA).